The injection is commonly used in clinical settings that involve acute or unstable symptom patterns. The injection is applied across domains where additional symptomatic support is needed for critical electrolyte imbalances.

This medication is relevant for managing acute symptomatic hypocalcemia (low calcium), severe cardiotoxicity stemming from hyperkalemia or hypermagnesemia, and systemic toxicity symptoms related to acute fluoride or lead poisoning. The primary use is to support essential physiological stability.

“It is used in managing episodes of involuntary spasms and tetany, contributing to improved day-to-day comfort during periods of heightened symptoms.”

In these specific clinical scenarios, the injection assists with maintaining functional stability and supports the patient during difficult episodes by easing distress related to systemic imbalance. It is relevant for managing symptoms that create noticeable physiological strain and assists with maintaining essential stability across acute therapeutic contexts.

Fact Box: Symptom Management Focus
Symptom Domain	Neuromuscular Hyperexcitability (Tetany)
Context	Acute Metabolic Emergencies
Benefit	Assists with maintaining functional stability

The eligibility for receiving B.Braun Calcium Gluconicum 10% is strictly defined by regulatory documents, which establish specific prohibitions and conditional use rules.

Contraindicated Populations

Use is absolutely contraindicated in patients with pre-existing hypercalcemia (high blood calcium), hypercalciuria (high urinary calcium), ventricular fibrillation, or galactosaemia. The injection must not be used in patients receiving cardiac glycosides (e.g., Digoxin) due to the severe risk of potentiated cardiotoxicity. A co-therapy restriction also exists: neonates (28 days of age or younger) receiving the antibiotic ceftriaxone are strictly contraindicated due to the risk of fatal precipitation.

Conditional Eligibility and Restrictions

Adult and pediatric patients are eligible for standard use, but specific conditions require caution. Patients with renal impairment must only receive the injection after careful assessment and should not receive repeated or prolonged treatment. Use is conditional and requires cautious indication establishment in individuals with heart diseases, sarcoidosis, or nephrocalcinosis. For older adults, cautious dosing, starting at the low end of the range, is recommended due to potential impaired renal function. During pregnancy, use is permitted only if clearly essential, and requires close monitoring to avoid hypercalcaemia. For lactation, a regulatory decision is required to either discontinue breastfeeding or abstain from therapy.

Interactions with other medicines and products

The official regulatory interaction profile for B.Braun Calcium Gluconicum 10% injection defines constraints across three areas: pharmacodynamic risk, exposure modification, and physical incompatibility.

Contravened Combinations and Restrictions Intravenous administration is contraindicated in patients receiving Cardiac Glycosides (such as Digoxin) due to the documented risk of potentiated arrhythmogenic and cardiotoxic effects. Procedural restrictions mandate that the injection must not be administered simultaneously via a Y-site with the antibiotic Ceftriaxone in any age group to prevent precipitation; this is classified as a formal contraindication in neonates (28 days of age or younger). Physical incompatibility rules require that the solution must not be co-mixed with fluids containing Phosphate or Bicarbonate, or with Minocycline Injection.

Pharmacodynamic and Exposure-Altering Interactions The preparation is documented to engage in pharmacodynamic antagonism, which can reduce the therapeutic effect of Calcium Channel Blockers. Furthermore, several medicinal products increase the potential for systemic calcium overexposure (hypercalcaemia). This exposure modification risk is documented with agents like Thiazide Diuretics, which reduce the renal excretion of calcium, and with co-administration of Vitamin D analogues or Vitamin A. This structure ensures that potential risks stemming from physical, systemic, or cardiovascular interactions are clearly defined as per regulatory standards.

How B.Braun Calcium Gluconicum 10% Works

B.Braun Calcium Gluconicum 10% delivers the essential calcium ion (Ca^2+), which exerts its pharmacodynamic effects through replacement and cofactor activity across three primary mechanistic domains.

Modulating Cellular Electrical Stability

In excitable cells, particularly myocardial and nerve tissue, the introduced Ca^2+ modulates the electrical charge across cell membranes. This interaction increases the cellular excitation threshold and reduces the tissue's overall responsiveness to stimuli. This action results in a lowered excitability threshold and altered electrical conduction kinetics.

Facilitating Muscle Contraction

Within muscle tissue, Ca^2+ is a critical internal signal for excitation-contraction coupling. The ion binds to Troponin C and related proteins, enabling the physical interaction between actin and myosin. This mechanism completes the necessary biochemical steps for force generation and muscle shortening.

Cofactor in Blood Clotting Cascades

In the plasma, Ca^2+ functions as an essential cofactor required to activate several specific Vitamin K-dependent coagulation factors (enzymes). This activation is crucial for enabling the precise, cascading reactions of hemostasis that culminate in the formation of a stable fibrin clot.

B.Braun Calcium Gluconicum 10% is formulated solely as a sterile solution for injection and is intended for the intravenous (IV) route of administration only. The injection protocol is designed for acute, short-term correction and is administered either as a slow, intermittent bolus or via continuous infusion.

Administration Method and Preparation

The 10% concentration is diluted in a compatible intravenous solution, such as 5% Dextrose or 0.9% Sodium Chloride, prior to infusion or slow injection. This preparation step creates a final concentration appropriate for the chosen administration method. The solution is visually inspected to ensure it is clear and free of particulate matter before use. The solution is incompatible with fluids containing phosphate and carbonate and is not mixed with them.

Dosing and Frequency

For adult acute needs, the standard initial bolus volume typically ranges from 10 mL to 20 mL (1,000 to 2,000 mg) of the 10% solution. This bolus is administered slowly, with the infusion rate not exceeding 200 mg per minute in adults. Subsequent doses may be administered on an as-needed, intermittent basis or transitioned to a continuous infusion, guided by patient assessment.

Population-Specific Use

Dosing for pediatric patients involves a weight-based calculation, differentiating it from adult protocols, and the maximum infusion rate is lower than the adult limit. For all patients, administration is generally confined to settings where proper procedural steps and close monitoring can be maintained, aligning with its function as an immediate, precise intervention.

Research Evidence Overview: B.Braun Calcium Gluconicum 10%

---

Evidence for Use in Acute Symptomatic Hypocalcaemia

The research exploring this injection for severely low calcium levels (acute symptomatic hypocalcaemia) includes small-scale randomized controlled trials (RCTs) and observational studies. These efforts monitor the rapid change in ionized serum calcium concentration and the short-term effect on symptoms like tetany (involuntary muscle spasms). Studies often report that administration was followed by a rapid, short-lived elevation in measured serum calcium levels. The short-lived nature of the effect is noted to necessitate subsequent monitoring or treatment. Comparative evidence against other calcium forms and long-term patient outcomes remain limited.

---

Evidence for Cardiac Membrane Stabilization

Evidence for using the injection to address heart abnormalities caused by severe hyperkalaemia (high potassium) or hypermagnesaemia is mainly based on observational studies and clinical consensus, as large RCTs are scarce in these emergencies. Research has examined the immediate effects on ECG abnormalities. Observational data describes patterns where administration coincided with a rapid shift in certain measured heart rhythm patterns. This stabilizing effect is temporary, often lasting less than an hour, and is generally followed by other therapies. Data for both cardiotoxicity indications are insufficient to conclusively link this immediate stabilization to long-term cardiac outcomes.

---

Gaps in the Research: What Remains Uncertain

The research landscape contains limitations common to emergency interventions. A key uncertainty is the lack of extensive, large-scale, randomized controlled trials to rigorously compare its use against alternatives. Evidence quality varies across studies, with much foundational data originating from smaller, older, or non-randomized cohorts. Data for certain groups, such as specific adult subgroups, and information on potential long-term effects beyond the immediate acute intervention remain insufficient to draw broad conclusions.

Key Studies & References

1. Calcium Gluconate - StatPearls - NCBI Bookshelf (NIH)
2. Management Algorithm for Adults with Hyperkalemia (K> 5.5 mEq/L) - ACEP Clinical Guideline
3. Hypermagnesemia: Treatment - Merck Manual Professional Edition

Common questions about B.Braun Calcium Gluconicum 10% (FAQ)

Q: How long does the effect of B.Braun Calcium Gluconicum 10% usually last?

A: Studies and official information indicate that the biological effects of this injection are typically short. For example, when used to stabilize heart rhythm, the documented duration of the immediate effect is typically short, often lasting around 20 to 60 minutes. Subsequent monitoring or additional treatment is necessary due to the temporary nature of the effect.

Q: Is B.Braun Calcium Gluconicum 10% used for emergency situations only?

A: The medication is primarily indicated for the acute, or immediate, treatment of symptomatic low calcium levels (hypocalcemia). Its intended function is for the rapid, high-speed correction of critical physiological issues, such as severe neuromuscular or cardiac instability.

Q: Does B.Braun Calcium Gluconicum 10% contain any sugar or sweeteners?

A: The official product information lists Calcium Gluconate and Water for Injection, often with a stabilizer like calcium saccharate, as the primary components. Official product information typically does not list sugar or sweeteners as added excipients. However, the preparation may be diluted in a Dextrose 5% solution, which contains sugar, prior to being administered intravenously.

Q: Can B.Braun Calcium Gluconicum 10% affect my blood pressure?

A: A decrease in blood pressure (hypotension) is a documented adverse reaction listed in the official product information. This effect is most often associated with the injection being administered too rapidly through the vein.

Q: What's the difference between Calcium Gluconate and Calcium Chloride?

A: The gluconate form is generally considered to carry a lower risk of local irritation or tissue damage if the solution leaks outside the vein compared to Calcium Chloride. However, the Calcium Chloride solution typically provides a higher concentration of elemental calcium for the same volume.

Q: What are the most common side effects of B.Braun Calcium Gluconicum 10% that people notice?

A: The product label highlights local reactions at the injection site, such as inflammation and pain due to leakage (extravasation), as specific safety concerns. Other effects that may be noticed include nausea, vomiting, a generalized feeling of hotness or flushing, and low blood pressure (hypotension).

Q: Is it normal to feel a warming sensation when B.Braun Calcium Gluconicum 10% is injected?

A: A transient feeling of hotness or flushing, often felt over the face, neck, and chest, is listed in the official product information as an effect commonly associated with the intravenous administration of calcium salts.

Q: What happens if B.Braun Calcium Gluconicum 10% leaks outside the vein during injection?

A: If the solution leaks outside the vein (extravasation), regulatory information indicates that local reactions, including pain, swelling, and severe tissue irritation, can occur. This potential for tissue death (necrosis) or abscess formation means the injection site must be closely monitored.

Q: Can B.Braun Calcium Gluconicum 10% cause issues with the heart rhythm?

A: The regulatory safety information lists cardiac disorders such as a slow heart rate (bradycardia), irregular heartbeats (arrhythmia), and circulatory collapse as potential adverse reactions. Due to the potential for cardiac issues, regulatory documents specify that close monitoring, including heart monitoring, is necessary during administration.

Q: Are there any long-term effects from receiving B.Braun Calcium Gluconicum 10%?

A: The official regulatory documents state that the safety of this injection has not been established for prolonged or repeated long-term use. It is indicated only for acute, short-term correction, and is not designed for chronic calcium replacement therapy.

Q: Does taking Vitamin D supplements interfere with B.Braun Calcium Gluconicum 10%?

A: Official regulatory interaction profiles indicate that co-administration of Vitamin D analogues can increase the risk of systemic calcium overexposure (hypercalcaemia). This is because Vitamin D enhances the body's absorption of calcium.

Q: Is it safe to get B.Braun Calcium Gluconicum 10% if I'm on diuretics ('water pills')?

A: Regulatory information highlights that caution is necessary with certain diuretics. Specifically, Thiazide Diuretics are known to reduce the excretion of calcium by the kidneys, which can increase the risk of excessive blood calcium levels (hypercalcaemia).

Q: What are the signs of having too much calcium (hypercalcemia) from this injection?

A: The symptoms of excessive blood calcium (hypercalcemia) may include increased thirst, frequent urination, confusion, or muscle weakness. Close monitoring of blood calcium levels is necessary after receiving the injection.

Q: Can the infusion speed of B.Braun Calcium Gluconicum 10% cause side effects?

A: Yes. Official labeling indicates that several adverse systemic effects are associated with too rapid intravenous administration. These include a sudden drop in blood pressure, a feeling of hotness, and disturbances to heart rhythm.

Q: What is the difference in elemental calcium between B.Braun Calcium Gluconicum 10% and other calcium forms?

A: Elemental calcium is the amount of biologically active calcium available in the compound. Official regulatory documents specify that one gram (1,000 mg) of the Calcium Gluconate salt provides approximately 93 mg of elemental calcium.

Q: Does B.Braun Calcium Gluconicum 10% contain preservatives?

A: Official drug descriptions typically state that this preparation contains no added preservative. It is supplied as a sterile solution and is intended for single use, meaning any unused portion must be discarded immediately after use.

Q: Is B.Braun Calcium Gluconicum 10% used to treat low calcium levels (hypocalcemia) in newborns?

A: The injection is indicated for the treatment of acute, symptomatic low calcium levels (hypocalcemia) in the pediatric population, including neonates (newborns). While it is indicated for newborns, specific weight-based dosing and close monitoring are necessary as per regulatory guidance.

Q: Could B.Braun Calcium Gluconicum 10% cause kidney stones over time?

A: The injection is not indicated for long-term use. Chronically elevated calcium levels (hypercalcemia), which can occur in patients with underlying issues, are generally linked to the formation of calcium renal stones.

Q: Is it necessary to monitor blood calcium levels after receiving B.Braun Calcium Gluconicum 10%?

A: Yes. Official product labeling specifies that both plasma calcium levels and ECG (heart rhythm) monitoring are necessary when the injection is administered. This is a crucial safety measure during and following the procedure.

Q: Why is the calcium gluconate form often preferred over calcium chloride for intravenous use?

A: The gluconate form is commonly preferred in many clinical situations because it poses a significantly lower risk of causing severe irritation, pain, or tissue necrosis (tissue damage) if it is inadvertently injected outside the vein.

Q: What is the role of Calcium Gluconate in treating hydrofluoric acid burns?

A: Regulatory guidance for specific toxic exposures indicates that Calcium Gluconate may be used for hydrofluoric acid burns. It provides calcium ions that chemically bind with free fluoride ions to help prevent or reduce severe fluoride toxicity and tissue damage.

Q: How does the body eliminate or process B.Braun Calcium Gluconicum 10% after it's administered?

A: Excess calcium delivered by the injection is incorporated into the body’s pool and is then processed by the body's natural regulatory systems. Primary elimination occurs through the renal system (kidneys).

Q: Is it common for B.Braun Calcium Gluconicum 10% to be mixed with other IV fluids?

A: The solution is generally diluted in compatible intravenous fluids, such as 5% Dextrose or normal saline, prior to administration. However, it is explicitly incompatible and must never be mixed with any solution containing phosphate or bicarbonate.

Q: Is B.Braun Calcium Gluconicum 10% part of a standard resuscitation kit?

A: Yes. Based on official emergency medical guidelines, Calcium Gluconate is cited for use in the context of cardiac resuscitation. It is specifically administered during cardiac arrest that is known or suspected to be caused by high potassium (hyperkalemia) or high magnesium levels.

Storage and Disposal of Calcium Gluconate Injection

Official regulatory documents define strict environmental and handling rules to maintain the integrity of B.Braun Calcium Gluconate Injection.

Storage Requirement	Rule
Temperature	Store at controlled room temperature.
Light Protection	Protect from light until use.
Physical Check	Must be visually inspected; do not use if particulate matter or discoloration is present.

The solution must be kept out of the sight and reach of children.

Stability and Disposal

The product is intended for single use only. Any unused solution in a single-dose container must be discarded immediately. If using a Pharmacy Bulk Package (PBP), dispensing must be completed within four hours of initial penetration. All unused solutions or waste material must be disposed of according to local regulations.